Ocugen Extends Cash Runway to 2028 With $130M Convertible, but CMO Vacancy and Stock Slide Test Investor Patience

Ocugen raises $130M via convertible notes to extend liquidity to 2028 but loses chief medical officer amid late-stage gene therapy filings, sending shares down 21% in 30 days.

Ocugen entered the final week of May with two major developments that pulled investor sentiment in opposite directions. A $130 million convertible note placement bolstered the balance sheet, extending the biotech group’s liquidity runway to 2028. Yet the same day, the company parted ways with its chief medical officer – a sudden leadership gap at a moment when three late-stage gene therapy programs are converging on FDA filing deadlines.

Shares have felt the strain. The stock closed Friday at €1.18, a modest 1.55% gain on the day but a 2.16% decline over the week. Over the past 30 days, the equity has lost more than a fifth of its value, sliding 21.60% amid concerns over dilution from the convertible debt and lingering doubts about the pace of clinical execution.

Convertible Debt Cuts Borrowing Costs, But Dilution Overhang Remains

Ocugen placed $115 million in convertible notes with a 6.75% coupon and 2034 maturity, plus a full exercise of an overallotment option that added another $15 million, bringing gross proceeds to $130 million. The notes were issued at 90% of par.

Roughly $32.7 million of the proceeds went to repay a high-cost loan from Avenue Capital Group. The remaining funds, after settling existing liabilities, leave the company with an estimated $112 million in cash. If outstanding warrants held by Janus Henderson are exercised, the cash position could rise to as much as $127 million.

The refinancing lowers Ocugen’s cost of debt and removes a near-term liquidity crunch. But the market is focusing on the flip side: convertible instruments typically carry equity conversion features, and the prospect of future dilution has weighed on the stock.

Chief Medical Officer Departure Adds Uncertainty

On May 8, 2026, Huma Qamar stepped down as chief medical officer without public explanation. The same day, Mohamed Genead assumed the role of interim CMO. Whether Genead will be a permanent appointment or a temporary bridge remains unclear.

The timing is particularly sensitive. Ocugen’s lead asset, OCU400 – a modifier gene therapy for retinitis pigmentosa – is gearing up for a rolling biologics license application (BLA) with the FDA. The submission is scheduled to begin in the third quarter of 2026, with a complete filing expected by mid-2027. Process-qualification batches for manufacturing are slated for completion in the second quarter of 2026. A change in regulatory leadership mid-stride could raise questions about continuity.

Pipeline Progress and Funding Plan Coincide

Management has outlined an ambitious goal: three late-stage programs targeting three BLA submissions by 2028. The OCU400 Phase 3 study covers more than 25 genetic mutations, underscoring the platform’s gene-agnostic approach.

For OCU410ST, the Stargardt disease candidate, an interim analysis of 24 patients after eight months is expected in the third quarter of 2026, with topline results likely in the second quarter of 2027.

Ocugen reported first-quarter results that provided a few surprises. Operating expenses climbed to $19.4 million from $16.0 million a year earlier. The net loss per share came in at $0.06, slightly above the consensus estimate of $0.05. Revenue, however, exceeded expectations at $1.53 million versus roughly $500,000 forecast by analysts.

Technical Indicators Flash Warning, Analysts Look Past the Pain

From a technical perspective, the stock is under water. It trades about 23% below its 50-day moving average of €1.53 and roughly 9% below the 200-day average of €1.30. The current price represents a 45% drop from the 52-week high of €2.17 hit in March. The relative strength index sits near 30.7 – close to oversold territory, but without a clear catalyst, buyers have stayed on the sidelines.

Resistance levels stand at €1.30 (200-day line) and €1.40 in the near term. A sustained move above €1.30 would be the first convincing sign of stabilization.

Wall Street, however, is not shying away. Seven analysts covering Ocugen rate the stock a “Strong Buy” on average, with a 12-month price target of $11.57 – a level that seems distant from the current €1.18 but reflects conviction that the pipeline’s value is not yet reflected in the market price.

The next public test arrives at the end of May, when Ocugen presents its gene therapy platform at the virtual Stifel 2026 Ophthalmology Forum. For a company juggling a fresh balance sheet, an interim CMO, and a skeptical market, the presentation offers a chance to refocus attention on clinical milestones rather than near-term volatility.